SynthesisFrontiers in pharmacology2022

Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer.

Yihang Qi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.